Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 353

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 353
---
 lifestyle for future success. These sessions are educational and aim to assist our customers to reach their long -term, sustainable goals. After the session and their updated habit plan is provided, customers are invited to repurchase the “Continuous Evolution Kit” to perpetuate their lifestyle improvement, thus creating a continuous cycle of health improvement. Customers also have the option to purchase individual telemedicine sessions, if needed. 181 Heritas Diagnostics: Clinical Diagnostics, Prognosis, and Monitoring Heritas Diagnostics offers a comprehensive suite of genetic tests that processes high -qualitygenetic and clinical data, instrumental in enhancing clinical healthcare decisions. The tests are designed to supply precise genetic insights to doctors, patients, and their families for diagnosis, prognosis and monitoring, allowing them to make informed treatment decisions over various conditions. Currently, we offer these services in Argentina and Paraguay and have contracts with two medical geneticists specializing in oncology and clinical genomics who provide counseling as needed. The tests and services are distributed as a business -to -business(B2B) service, through partnerships with clinical laboratories, who we empower to offer advanced diagnostic services to their customers, who are health system stakeholders, such as patients, providers, government agencies, pharmacies, and/or private health institutions. Patient samples, including blood, tissue biopsies, saliva, plasma or nucleic acids, are collected through these clinical laboratories and processed in our Argentine Wet -Labaccording to the specific analysis required. Our genetic tests are designed for high accuracy in detection and profiling, utilizing sophisticated bioinformatics tools to decipher complex genetic information, and provide a wide array of clinically actionable insights. Reproductive Genetics: Non-Invasive Prenatal Testing (“NIPT”) We have developed a proprietary non -invasiveprenatal screening test which incorporates a proprietary developed bioinformatics pipeline to analyze fetal DNA from maternal blood samples. The test, which can be administered from nine weeks of pregnancy through birth, screens for common genetic alterations including Down, Edwards, and Patau syndromes, sex chromosome abnormalities, specific aneuploidies, and pathogenic microdeletions/microduplications that could result in a range of genetic disorders. Our NIPT also determines the sex of the fetus and is recommended for all pregnant women, regardless of age and/or risk. Oncology: Hereditary Cancer Test This genetic test is designed to detect inherited mutations linked to an increased risk of hereditary cancers, including breast, ovarian, pancreatic, gastric, uterine, prostate, and renal cancers. Utilizing